comprehensive -WSS

comprehensive

author：comprehensive 2025-09-28 01:35:49 - browse：1

UnitedHealth Group’s Optum subsidiary saw a lower operating margin in the second quarter due to more seniors getting care, a spike in demand for behavioral health services, and an influx of members with higher health needs.

“Those three elements, the senior trend piece, the behavioral piece, and then the effects of the strong growth is really what explains what’s going on,” UnitedHealth Group CEO Andrew Witty said on the company’s earnings call on Friday. “We’ll continue to lean into that growth very assertively.”

Minnetonka, Minn.-based UnitedHealth Group’s Optum segment, which includes its provider arm, its pharmacy benefit manager, and its data and technology arm, reported an operating margin of 6.6% in the quarter ended June 30, compared with 7.3% in the prior-year period. Leaders said the decline was within its provider arm, Optum Health.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： As Taiwan prepares for anti

knowledge

WSS

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

BMI, flaws aside, is found to be useful estimate of body fat in youth

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

At ASCO, AstraZeneca reports strong data for breast cancer drug

Elizabeth Warren probes abortion access

leisure time

comprehensive

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

At ASCO, AstraZeneca reports strong data for breast cancer drug

Activists slam private health insurers over coverage restrictions

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Medicare details structure of new drug price negotiation program

BMI, flaws aside, is found to be useful estimate of body fat in youth

Jerome Adams on the need for new antivirals for Covid

7 of the most gruesome medical devices in history

23andMe had bad news about my health. I wish a person had delivered it

With trial win, GSK could get blood cancer drug back on market

leisure time

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Providers still hesitate to prescribe buprenorphine, study finds

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Marvel Studios reveals new trailer for 'The Marvels': Watch here

focus

knowledge

focus

knowledge